Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2834772 | 0.99 | KDM4E (0.79) | KDM4EALDH1A1 | |
| SCHEMBL26005846 | 0.90 | KDM4E (1.00) | KDM4EALDH1A1 | |
| SCHEMBL9684763 | 0.90 | KDM4E (0.67) | KDM4EALDH1A1 | |
| SCHEMBL30215511 | 0.90 | KDM4E (1.00) | KDM4EALDH1A1 | |
| SCHEMBL9684727 | 0.89 | KDM4E (0.70) | KDM4EALDH1A1 | |
| SCHEMBL9684654 | 0.89 | KDM4E (0.66) | KDM4EALDH1A1 | |
| SCHEMBL27727441 | 0.89 | KDM4E (0.72) | KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL27727464 | 0.87 | KDM4E (0.71) | KDM4EALDH1A1 | |
| SCHEMBL9685162 | 0.87 | KDM4E (0.86) | KDM4EALDH1A1 | |
| SCHEMBL27727438 | 0.86 | KDM4E (0.69) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552440-A1 | NOVEL COMBINATION AND USE | Helperby Therapeutics Limited (GB) | 2013-02-06 | — | — | EP | claimed |
| WO-2011121345-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2011-10-06 | — | — | WO | claimed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | claimed |
| EP-2086542-A1 | TOPICAL FORMULATIONS | Helperby Therapeutics Limited (GB) | 2009-08-12 | — | — | EP | claimed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| WO-2008056151-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2008-05-15 | — | — | WO | claimed |
| EP-0307078-B1 | QUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1992-08-26 | — | — | EP | claimed |
| US-5051508-A | Antisecretory agents and enzyme inhibitors as antiulcer agents | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1991-09-24 | — | — | US | claimed |
| EP-0307078-A1 | Quinoline derivatives, process for their preparation and pharmaceutical compositions containing them | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1989-03-15 | — | — | EP | claimed |
| EP-3228314-B1 | SULOCTIDIL FOR USE TO TREAT MICROBIAL INFECTIONS | HELPERBY THERAPEUTICS LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-10265373-B2 | Pharmaceutical composition and method of treating a microbial infection with sulcotidil | HELPERBY THERAPEUTICS LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| WO-2018162928-A1 | METHOD FOR RESTORING EFFICACY OF AN ANTIBACTERIAL AGENT | HELPERBY THERAPEUTICS LIMITED (GB) | 2018-09-13 | — | — | WO | disclosed |
| US-9789101-B2 | Methods and compositions for treating microbial infection using pyrroloquinone | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| EP-3228314-A1 | VASODILATOR FOR USE TO TREAT MICROBIAL INFECTIONS | Helperby Therapeutics Limited (GB) | 2017-10-11 | — | — | EP | disclosed |
| WO-2011121345-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| US-20100093691-A1 | TOPICAL FORMULATIONS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-0307078-B1 | QUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1992-08-26 | — | — | EP | disclosed |
| US-5051508-A | Antisecretory agents and enzyme inhibitors as antiulcer agents | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1991-09-24 | — | — | US | disclosed |
| EP-0307078-A1 | Quinoline derivatives, process for their preparation and pharmaceutical compositions containing them | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137622-A1 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | LPO, ARG1, CTSL | KDM4E 1494/4885ALDH1A1 865/4885 |
| US-20100093691-A1 | TOPICAL FORMULATIONS | DPM1, SUCLG1, LSS | KDM4E 2890/4885ALDH1A1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.